(2003; 67 pages)
5.4 Recommendations for quality and bio-equivalence surveillance
Despite the logistical problems, this study demonstrated that there is a significant problem of low quality. In view of the potential danger that substandard antimalarials could already be posing in the fight against malaria in the region, there was enough justification to recommend definitive action to be taken at country level to address this problem. The WHO Roll Back Malaria Programme should assist countries to take measures to minimize poor quality antimalarial products reaching patients. Such measures should include: promoting good procurement practices in the public sector; monitoring and supporting manufacturers' and suppliers' GMP compliance; and supporting the implementation of sound and effective post-marketing surveillance programmes within drug regulatory authorities, to ensure safe use of good quality antimalarial products.